Invesco Biotechnology & Genome ETF (PBE)

NYSEARCA: PBE · IEX Real-Time Price · USD
64.64
-0.50 (-0.76%)
At close: Mar 28, 2024, 3:59 PM
64.72
+0.08 (0.12%)
After-hours: Mar 28, 2024, 8:00 PM EDT
-0.76%
Assets $244.90M
Expense Ratio 0.58%
PE Ratio 17.15
Shares Out 3.79M
Dividend (ttm) $0.04
Dividend Yield 0.06%
Ex-Dividend Date Mar 18, 2024
Payout Ratio 1.02%
1-Year Return +5.75%
Volume 3,967
Open 65.12
Previous Close 65.14
Day's Range 64.64 - 65.20
52-Week Low 52.47
52-Week High 67.76
Beta 0.91
Holdings 32
Inception Date Jun 23, 2005

About PBE

Fund Home Page

The Invesco Biotechnology & Genome ETF (PBE) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tiered equal-weighted index of companies principally engaged in biotechnology and genetic engineering. PBE was launched on Jun 23, 2005 and is issued by Invesco.

Asset Class Equity
Stock Exchange NYSEARCA
Ticker Symbol PBE
ETF Provider Invesco
Index Tracked Dynamic Biotech & Genome Intellidex Index (AMEX)

Top 10 Holdings

46.39% of assets
Name Symbol Weight
Neurocrine Biosciences, Inc. NBIX 5.10%
Regeneron Pharmaceuticals, Inc. REGN 5.01%
Gilead Sciences, Inc. GILD 4.98%
Amgen Inc. AMGN 4.96%
BioMarin Pharmaceutical Inc. BMRN 4.91%
Vertex Pharmaceuticals Incorporated VRTX 4.87%
Bio-Techne Corporation TECH 4.85%
Biogen Inc. BIIB 4.85%
MannKind Corporation MNKD 3.45%
Collegium Pharmaceutical, Inc. COLL 3.42%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Mar 18, 2024 $0.02419 Mar 22, 2024
Jun 20, 2023 $0.01407 Jun 23, 2023
Mar 23, 2020 $0.02898 Mar 31, 2020
Sep 24, 2018 $0.00207 Sep 28, 2018
Jun 16, 2017 $0.21532 Jun 30, 2017
Mar 17, 2017 $0.05552 Mar 31, 2017
Full Dividend History

News

9 Best Biotech ETFs to Play High-Octane Trends

Biotechnology is a dynamic but often volatile industry. These biotech ETFs provide a lower-risk way to invest in the space.

2 years ago - Kiplinger

5 Top ETFs With Exposure To Biogen

For the first time in 18 years, there was a new treatment for Alzheimer's Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that can reduce the clinical dec...

Other symbols: BIIBBBHFBTIBBPKW
3 years ago - Benzinga

3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover

The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexio...

Other symbols: BBHFBT
3 years ago - Benzinga

2 Biotech Funds Poised for a Healthy Breakout

Biotech stocks are likely to remain in focus through year end amid news surrounding COVID-19 vaccines and treatments.

Other symbols: IBB
3 years ago - Investopedia

3 Health Care ETFs Where Components Are Enduring Downgrades

After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.

Other symbols: BTECPTH
3 years ago - Benzinga

6 Best Biotech ETFs to Buy for Cutting-Edge Growth

Biotech ETFs are, in a word, hot.

Other symbols: BTECCNCRGERMIBBXBI
3 years ago - Kiplinger

Where to Buy Booming Biotech ETFs

Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.

Other symbols: LABUXBI
4 years ago - Investopedia

Investors flee Biotech ETFs as they Lag Bull Market

Many biotech ETFs and other funds have fallen sharply off their highs in recent months.

Other symbols: IBBXBI
4 years ago - Investopedia

3 Charts That Suggest Now Is the Time to Buy Into Biotech

Most of the financial markets have trended lower in recent weeks, but biotech seems to have countered the trend.

Other symbols: INCYIONS
5 years ago - Investopedia